Figure 1
Figure 1. Schematic illustration of the experimental setup. Mice were injected intravenously with 105 Renca-Her2/Neu tumor cells on day 0. On day 7, mice were irradiated with 200 or 400 rads total body irradiation (TBI). A split dose of T-bodies (prepared by transduction of naive T cells with a Her2/neu-specific CAR, or isolated from transgenic mice expressing this CAR) was given on days 8 and 10. The CAR is composed of a scFv fused to CD28 and FcRγ signaling domains. T-bodies were derived from mice of either the C57BL/6 (allogeneic) or Balb/c (syngeneic) background.

Schematic illustration of the experimental setup. Mice were injected intravenously with 105 Renca-Her2/Neu tumor cells on day 0. On day 7, mice were irradiated with 200 or 400 rads total body irradiation (TBI). A split dose of T-bodies (prepared by transduction of naive T cells with a Her2/neu-specific CAR, or isolated from transgenic mice expressing this CAR) was given on days 8 and 10. The CAR is composed of a scFv fused to CD28 and FcRγ signaling domains. T-bodies were derived from mice of either the C57BL/6 (allogeneic) or Balb/c (syngeneic) background.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal